Latest news with #UVAHealth
Yahoo
7 days ago
- Yahoo
Man charged in shooting connected to Waynesboro road rage incident
The Waynesboro Police Department has arrested a man accused of shooting a juvenile in connection with a recent road rage incident. At approximately 3:30 p.m. on Aug. 3, Waynesboro police responded to Moonshine Market at 1001 E. Main St. following a report of a gunshot victim. Police found a 16-year-old boy with a gunshot wound that was not considered life-threatening. The teen was taken to UVA Health in Charlottesville. Initial findings suggest the incident stemmed from a road rage altercation in the 700 block of North Commerce Avenue, police said. On Aug. 7, Tyleik Cabell, 23, of Waynesboro, turned himself in at the Waynesboro Police Department. He is charged with maliciously shooting at an occupied vehicle. Following his arrest, Cabell was released on a $5,000 unsecured bond. More: Craigsville native Tony Schiavone pumped for wresting return to Roanoke in AEW Collision More: Cat Nap Coffee Roasting Cafe plans grand opening in Staunton Brad Zinn is the cops, courts and breaking news reporter at The News Leader. Have a news tip? Or something that needs investigating? You can email reporter Brad Zinn (he/him) at bzinn@ You can also follow him on X (formerly Twitter). This article originally appeared on Staunton News Leader: Man charged in shooting connected to Waynesboro road rage incident
Yahoo
05-08-2025
- Yahoo
Teen shot in Waynesboro in road rage incident
Authorities in Waynesboro are investigating a road rage shooting that injured a juvenile over the weekend, a press release said. On August 3 at 3:29 p.m., officers from the Waynesboro Police Department responded to Moonshine Market at 1001 E. Main St. following a report of a victim with a gunshot wound. Police found a 16-year-old boy with injuries that were not life-threatening, the release said. The teen was taken to UVA Health in Charlottesville. Initial findings suggest the incident stemmed from a road rage altercation in the 700 block of North Commerce Avenue, according to police. The investigation is ongoing. More: National Night Out happening Aug. 5 in Augusta County More: Law change spearheaded by local attorney ends juvenile shackling in courtrooms Brad Zinn is the cops, courts and breaking news reporter at The News Leader. Have a news tip? Or something that needs investigating? You can email reporter Brad Zinn (he/him) at bzinn@ You can also follow him on X (formerly Twitter). This article originally appeared on Staunton News Leader: Teen shot in Waynesboro in road rage incident
Hans India
28-05-2025
- Health
- Hans India
Low-cost HIV drug to improve vision in patients with common diabetes complication
New Delhi: An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more effectively, according to preliminary results of a clinical trial. The drug, lamivudine, could represent an important new option for millions of patients with diabetic macular edema (DME) -- a condition affecting about one in 14 people with diabetes. It causes fluid to build up in the retina of the eye and affects vision. As the drug is taken orally it potentially offers patients an alternative to monthly injections directly into their eyes, said the researchers from the University of Virginia in the US. "The mechanism of action of lamivudine is also different from that of existing treatments, so we could also develop combination therapies," said researcher Jayakrishna Ambati, from UVA Health's Center for Advanced Vision Science. The researchers explained that lamivudine is effective against DME because it blocks the activity of inflammasomes -- important agents of our immune systems. Inflammasomes normally act as sensors of infections, but they have also been implicated in the development of DME. For the study, published in the journal Med, the researchers enrolled two dozen adults with DME in a small randomised clinical trial. Participants were randomly assigned to receive either lamivudine or a harmless placebo, in addition to injections of the drug bevacizumab into their eyes starting after four weeks. Participants who received lamivudine showed significant vision improvements even before their first eye injections. Their ability to read letters on an eye chart improved by 9.8 letters (about 2 lines on the eye chart) at four weeks, while the participants receiving a placebo saw their ability decrease by 1.8 letters. A month after the bevacizumab injections, the lamivudine recipients had improved by a whopping 16.9 letters (more than 3 lines on the eye chart), while the placebo group, receiving bevacizumab alone, had increased by only 5.3. The results suggest that lamivudine may work both alone and in conjunction with bevacizumab injections, though larger studies will be needed to bear that out, the researchers said. Lamivudine alone could be life-changing for patients in many areas of the world with limited access to specialty doctors or who are unable to afford or travel to monthly eye appointments, Ambati said, while calling for more trials of lamivudine with larger numbers of patients.
Yahoo
24-05-2025
- Health
- Yahoo
Virginia health officials confirm state's second case of measles in teen
The Brief A second case of measles has been confirmed in Virginia. State health officials say the patient is a teen between the ages of 13 and 17. There are several potential exposure sites that you can see below. RICHMOND, Va. - The Virginia Department of Health has confirmed the state's second case of measles. They say the patient is a teenager between the ages of 13 and 17 in the Northwest region who recently traveled internationally. What you need to know Below are the dates, times, and locations of potential exposure sites in Virginia: Charlottesville Albemarle Airport on Tuesday, May 20 between 2:15 p.m. and 5:30 p.m. Play it Again Sports, located at 1885 Seminole Trail in Charlottesville on Tuesday, May 20 from 2:40 p.m. to 5 p.m. Goodwill Store and Donation Center, located at 440 Gander Drive in Charlottesville on Tuesday, May 20 from 3:10 p.m. to 5:30 p.m. UVA Health Primary Care Riverside, located at 2335 Seminole Lane, Suite 200 in Charlottesville on Thursday, May 22 from 2 p.m. to 7:10 p.m. UVA Health University Medical Center Emergency Department, located at 1215 Lee St. in Charlottesville on Friday, May 23 from 12 a.m. to 6 a.m. Dig deeper The state's first case of measles was diagnosed in April. The infected patient was a child up to four years old who recently traveled internationally prior to testing positive. The potential exposure site in that case was a Kaiser Permanente Caton Hill Medical Center Advanced Urgent Care in Northern Virginia. Health officials said the child had visited the center while contagious. Why you should care Measles is highly contagious all year round. The Virginia Department of Health says anyone exposed is considered to "be at risk of developing measles and should contact their healthcare provider immediately." The Virginia Department of Health goes on to say those exposed should watch for symptoms for three weeks after the date of the potential exposure. Measles symptoms include fever, runny nose and watery eyes before a rash appears on the face and body. If symptoms of measles are noticed, the person exposed should immediately self-isolate by staying home.
Medical News Today
12-05-2025
- Health
- Medical News Today
Alzheimer's: HIV drugs may offer ‘significant' protection
New research suggests that HIV drugs may have a protective effect against Alzheimer's. Willie B. Thomas/Getty Images Researchers at UVA Health have found that a class of HIV drugs called nucleotide reverse transcriptase inhibitors (NRTIs) may significantly reduce the risk of developing Alzheimer's disease. Their large-scale analysis of United States health insurance data revealed that patients taking these medications had up to a 13% lower risk of Alzheimer's disease each year. Based on these findings, the team is calling for clinical trials to test whether these drugs could be used to help prevent Alzheimer's. In their new research, they found that people taking these medications are significantly less likely to develop the condition. The team had earlier discovered a possible biological mechanism explaining how the drugs might offer protection against Alzheimer's. Alzheimer's disease is the leading cause of dementia, responsible for approximately 60% to 80% of all cases in the United States. It most commonly begins in individuals ages 65 and older. Motivated by this, the researchers examined two major U.S. health insurance databases and found that the risk of developing Alzheimer's dropped by 6% per year in one dataset and by 13% per year in the other among patients on NRTIs. Jayakrishna Ambati, MD, founding director of UVA's Centre for Advanced Vision Science and a professor in the Department of Ophthalmology at the University of Virginia School of Medicine, and senior of the study, explained the key findings to Medical News Today : 'We analysed health insurance databases of tens of millions of people and made the surprising discovery that people taking a group of anti-HIV drugs called NRTIs had a ~10% reduction in the risk of developing Alzheimer's disease for every year that they took these drugs.' — Jayakrishna Ambati, MD NRTIs are commonly used to stop HIV from replicating in the body. However, Jayakrishna Ambati and his research team had previously found that these drugs also block the activation of inflammasomes, key immune system components that have been linked to the development of Alzheimer's disease. This discovery led them to investigate whether patients taking NRTIs, which also treat hepatitis B, might have a lower risk of developing Alzheimer's. To explore this, the team analysed long-term health data from two major U.S. sources: 24 years of records from the Veterans Health Administration, which predominantly includes male patients, and 14 years from the MarketScan database, which covers a more diverse, commercially insured population. They focused on individuals ages 50 and older who were being treated for HIV or hepatitis B and who had no prior diagnosis of Alzheimer's. The researchers identified over 270,000 qualifying patients and assessed how many later developed Alzheimer's. After accounting for potential confounding factors, such as existing health conditions, they found that those taking NRTIs experienced a marked and meaningful reduction in Alzheimer's risk. The researchers observed that the reduced risk of Alzheimer's was specific to patients taking NRTIs and was not seen in those using other types of HIV medications. This distinction led them to conclude that NRTIs should be formally tested in clinical trials to assess their potential to prevent Alzheimer's disease. If proven effective, the impact could be substantial. With nearly 7 million Americans currently affected by Alzheimer's and projections indicating that number could double to 13 million by 2050, the need for preventive treatments is growing. In addition, the financial burden is expected to rise sharply, with the annual cost of care for Alzheimer's and related dementias projected to increase from $384 billion today to nearly $1 trillion in the coming decades, according to the Alzheimer's Association. 'It's estimated that 10 million people develop Alzheimer's disease around the world every year. A 10% reduction in risk could have a dramatic effect on the impact and burden of Alzheimer's,' Dr Ambati explained. 'There are some ongoing clinical trials of NRTIs in Alzheimer's disease that are showing some interesting anti-inflammatory effects. Since NRTIs can have some rare but serious side effects, we have developed a modified version called K9 that has the beneficial anti-inflammatory effect without those side effects. K9 is already in clinical for eye diseases, and we are planning to start trials in Alzheimer's disease as well.' — Jayakrishna Ambati James Giordano, PhD, Professor Emeritus of Neurology and Biochemistry, Georgetown University Medical Center, Washington, DC, who was not involved in the research, told MNT that 'this is an interesting retrospective study.' 'It provides evidence that use of nucleoside reverse transcriptase inhibitors (NRTIs) that have been used to treat human immunodeficiency virus (HIV), and which inhibit development of inflammasomes, is positively correlated to a reduced incidence of Alzheimer's disease.' 'This is noteworthy in that several lines of converging evidence have shown that bodily and cerebral inflammatory states can induce production of both tau and amyloid proteins in brain that are contributory to the pathology of [Alzheimer's],' Giordano added. 'Inflammasomes are cellular proteins that aggregate and form discrete structures both in response to tau and amyloid aggregation, as well as following certain viral and bacterial infections, trauma, alterations in immune function, and exposure to various stressful environmental factors.' —James Giordano, PhD 'Inflammasomes induce changes in mitochondrial function, cell metabolism, calcium regulation, can contribute to the formation of neural plaques and tangles, and can induce a form of cell death, which has been implied in the genesis of Alzheimer's,' Giordano explained. Inflammation, NRTIs, and Alzheimer's 'This study strengthens the hypothesis that inflammasome-mediated inflammatory processes are operative in Alzheimer's and offers potential direction for the development of NRTI type drugs and molecular agents aimed at mitigating inflammasome development as a viable treatment – or perhaps preventive intervention – for Alzheimer's.' —James Giordano, PhD
